146 related articles for article (PubMed ID: 37016331)
1. Plasma hPG
Prieur A; Harper A; Khan M; Vire B; Joubert D; Payen L; Kopciuk K
BMC Cancer; 2023 Apr; 23(1):305. PubMed ID: 37016331
[TBL] [Abstract][Full Text] [Related]
2. Plasma hPG
Dupuy M; Iltache S; Rivière B; Prieur A; Pageaux GP; Bedoya JU; Faure S; Guillaumée H; Assenat E
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053564
[TBL] [Abstract][Full Text] [Related]
3. Association between post-operative hPG
Doucet L; Cailleteau A; Vaugier L; Gourmelon C; Bureau M; Salaud C; Roualdes V; Samarut E; Aumont M; Zenatri M; Loussouarn D; Quillien V; Bocquet F; Payen-Gay L; Joubert D; Prieur A; Robert M; Frenel JS
ESMO Open; 2023 Oct; 8(5):101626. PubMed ID: 37713930
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Plasma hPG
Kohli M; Tan W; Vire B; Liaud P; Blairvacq M; Berthier F; Rouison D; Garnier G; Payen L; Cousin T; Joubert D; Prieur A
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33498444
[TBL] [Abstract][Full Text] [Related]
5. hPG
Chauhan A; Prieur A; Kolesar J; Arnold S; Payen L; Mahi Y; Vire B; Sands M; Evers BM; Joubert D; Anthony L
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205614
[TBL] [Abstract][Full Text] [Related]
6. [hPG
You B; Assenat E; Payen L; Mazard T; Glehen O; Calattini S; Villeneuve L; Lescuyer G; Vire B; Ychou M
Bull Cancer; 2022 Jun; 109(6):707-713. PubMed ID: 35597620
[TBL] [Abstract][Full Text] [Related]
7. The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients.
You B; Mercier F; Assenat E; Langlois-Jacques C; Glehen O; Soulé J; Payen L; Kepenekian V; Dupuy M; Belouin F; Morency E; Saywell V; Flacelière M; Elies P; Liaud P; Mazard T; Maucort-Boulch D; Tan W; Vire B; Villeneuve L; Ychou M; Kohli M; Joubert D; Prieur A
EBioMedicine; 2020 Jan; 51():102574. PubMed ID: 31877416
[TBL] [Abstract][Full Text] [Related]
8. hPG
Casile M; Passildas J; Vire B; Molnar I; Durando X
Front Neurol; 2022; 13():1073476. PubMed ID: 36712425
[TBL] [Abstract][Full Text] [Related]
9. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
10. A novel method to detect hPG
Cappellini M; Flaceliere M; Saywell V; Soule J; Blanc E; Belouin F; Ortiz E; Canterel-Thouennon L; Poupeau S; Tigrett S; Vire B; Liaud P; Blairvacq M; Joubert D; Prieur A
Anal Methods; 2021 Oct; 13(38):4468-4477. PubMed ID: 34494619
[TBL] [Abstract][Full Text] [Related]
11. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
12. Predictors of time to death after distant recurrence in breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2019 Jan; 173(2):465-474. PubMed ID: 30328050
[TBL] [Abstract][Full Text] [Related]
13. Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review.
Atakpa EC; Thorat MA; Cuzick J; Brentnall AR
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013091. PubMed ID: 34697802
[TBL] [Abstract][Full Text] [Related]
14. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study.
Allin KH; Nordestgaard BG; Flyger H; Bojesen SE
Breast Cancer Res; 2011 Jun; 13(3):R55. PubMed ID: 21639875
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
Li X; Zhang X; Liu J; Shen Y
BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
[TBL] [Abstract][Full Text] [Related]
16. Association of Serum Level of Vitamin D at Diagnosis With Breast Cancer Survival: A Case-Cohort Analysis in the Pathways Study.
Yao S; Kwan ML; Ergas IJ; Roh JM; Cheng TD; Hong CC; McCann SE; Tang L; Davis W; Liu S; Quesenberry CP; Lee MM; Ambrosone CB; Kushi LH
JAMA Oncol; 2017 Mar; 3(3):351-357. PubMed ID: 27832250
[TBL] [Abstract][Full Text] [Related]
17. Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy.
Baulies S; Belin L; Mallon P; Senechal C; Pierga JY; Cottu P; Sablin MP; Sastre X; Asselain B; Rouzier R; Reyal F
Br J Cancer; 2015 Jun; 113(1):30-6. PubMed ID: 26079300
[TBL] [Abstract][Full Text] [Related]
18. Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences.
Kimbung S; Kovács A; Bendahl PO; Malmström P; Fernö M; Hatschek T; Hedenfalk I
Mol Oncol; 2014 Feb; 8(1):119-28. PubMed ID: 24287398
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20. Progastrin: An Overview of Its Crucial Role in the Tumorigenesis of Gastrointestinal Cancers.
Fioretzaki R; Sarantis P; Charalampakis N; Christofidis K; Mylonakis A; Koustas E; Karamouzis MV; Sakellariou S; Schizas D
Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
